Start:
June 2011
End:
December 2024
Enrollment:
800
In this study, researchers will document the clinical features and biomarkers of people with synucleinopathies (Parkinson's disease, dementia with Lewy bodies, or multiple system atrophy) and those in a pre-dementia stage to better understand how these disorders evolve over time. Synucleinopathies are a group of rare diseases associated with worsening neurological deficits and abnormal accumulation of the protein alpha-synuclein in the nervous system. Researchers will follow people diagnosed with a synucleinopathy and those believed to be in a pre-dementia stage over a 5-year period. The study aims to find biological clues of disease progression that would allow for testing of disease-modifying strategies to delay or stop the neurodegenerative process.
Minimum Age: 18 Years
Maximum Age: N/A
Contact study personnel listed either under the general study contact or the location nearest you.
Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.
Massachusetts | |
---|---|
Beth Israel Deaconess Medical Center
Boston,
MA
Recruiting
Sharika Rajan | |
Michigan | |
University of Michigan
Ann Arbor,
MI
Recruiting
Arijit Bhaumik, BA | |
Minnesota | |
Mayo Clinic
Rochester,
MN
Recruiting
Tonette Gehrking | |
New York | |
NYU Medical Center
New York,
NY
10016
Recruiting
Jose Martinez, MA | |
Tennessee | |
Vanderbilt Univeristy
Nashville,
TN
Recruiting
Emily Garland, PhD |
Lead: New York University School of Medicine
Source: ClinicalTrials.gov ID: NCT01799915
An official website of the U.S. government, managed by the National Institute on Aging at the National Institutes of Health